A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Pfizer
M.D. Anderson Cancer Center
Novartis
Pfizer
National Cancer Institute (NCI)
Cancer Research UK
Nested Therapeutics, Inc
Ikena Oncology
Eli Lilly and Company